Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joanne Mortimer

Showing results (11-20 of 110) with videos related to

Pageof 11
Sort By:
The Journal of Steroid Biochemistry and Molecular Biology|May 23, 2015
From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?Victoria Shang Wu, Noriko Kanaya, Chiao Lo, et al.
Breast Cancer Research : BCR|March 1, 2019
Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trialJoanne Mortimer, Jack Di Palma, Kendra Schmid, et al.
Breast Cancer Research and Treatment|December 9, 2017
A single institution experience with palbociclib toxicity requiring dose modificationsJun Gong, May Cho, Kim Wai Yu, et al.
Clinical Breast Cancer|December 28, 2013
Phase I/II trial of vinorelbine and sorafenib in metastatic breast cancerThehang Luu, Paul Frankel, Cathie Chung, et al.
Oncotarget|July 10, 2015
SERPINA1 is a direct estrogen receptor target gene and a predictor of survival in breast cancer patientsHei Jason Chan, Haiqing Li, Zheng Liu, et al.
Cancer Treatment and Research Communications|June 14, 2025
Trop-2 expression as a biomarker of response to sacituzumab govitecan in patients with HER2-negative metastatic breast cancer: A pilot studyAlexis LeVee, Megan Wong, Nora Ruel, et al.
Annals of Surgical Oncology|September 29, 2021
A Cross-Sectional Study of Distress Levels in Patients with Newly Diagnosed Breast Cancer: The Impact of Race, Ethnicity, and Language PreferenceLorena Gonzalez, Canlan Sun, Matthew Loscalzo, et al.
The Oncologist|April 24, 2024
Impact of neoadjuvant pembrolizumab adherence on pathologic complete response in triple-negative breast cancer: a real-world analysisAlexis LeVee, Megan Wong, Sarah Flores, et al.
Annals of Diagnostic Pathology|November 20, 2024
Poor response of HER2-positive mucinous carcinomas of breast to neoadjuvant HER2-targeted therapy: A study of four casesMin Han, Daniel Schmolze, Javier A Arias-Stella, et al.
The Oncologist|June 23, 2025
Efficacy and immune-related adverse events of pembrolizumab with bone-modifying agents in female patients with breast cancerAlexis LeVee, Esther Peluso, Melissa G Lechner, et al.
Pageof 11

Showing results (11-20 of 110) with videos related to

Sort By:
Pageof 11
The Journal of Steroid Biochemistry and Molecular Biology|May 23, 2015
From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?Victoria Shang Wu, Noriko Kanaya, Chiao Lo, et al.
Breast Cancer Research : BCR|March 1, 2019
Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trialJoanne Mortimer, Jack Di Palma, Kendra Schmid, et al.
Breast Cancer Research and Treatment|December 9, 2017
A single institution experience with palbociclib toxicity requiring dose modificationsJun Gong, May Cho, Kim Wai Yu, et al.
Clinical Breast Cancer|December 28, 2013
Phase I/II trial of vinorelbine and sorafenib in metastatic breast cancerThehang Luu, Paul Frankel, Cathie Chung, et al.
Oncotarget|July 10, 2015
SERPINA1 is a direct estrogen receptor target gene and a predictor of survival in breast cancer patientsHei Jason Chan, Haiqing Li, Zheng Liu, et al.
Cancer Treatment and Research Communications|June 14, 2025
Trop-2 expression as a biomarker of response to sacituzumab govitecan in patients with HER2-negative metastatic breast cancer: A pilot studyAlexis LeVee, Megan Wong, Nora Ruel, et al.
Annals of Surgical Oncology|September 29, 2021
A Cross-Sectional Study of Distress Levels in Patients with Newly Diagnosed Breast Cancer: The Impact of Race, Ethnicity, and Language PreferenceLorena Gonzalez, Canlan Sun, Matthew Loscalzo, et al.
The Oncologist|April 24, 2024
Impact of neoadjuvant pembrolizumab adherence on pathologic complete response in triple-negative breast cancer: a real-world analysisAlexis LeVee, Megan Wong, Sarah Flores, et al.
Annals of Diagnostic Pathology|November 20, 2024
Poor response of HER2-positive mucinous carcinomas of breast to neoadjuvant HER2-targeted therapy: A study of four casesMin Han, Daniel Schmolze, Javier A Arias-Stella, et al.
The Oncologist|June 23, 2025
Efficacy and immune-related adverse events of pembrolizumab with bone-modifying agents in female patients with breast cancerAlexis LeVee, Esther Peluso, Melissa G Lechner, et al.
Pageof 11